The National Immunobiological Company, which is part of the Rostec State Corporation, was established in 2013 as a managing organization to form a holding company in the development and production of immunobiological products. The purpose of the holding is to ensure Russia's independence from the import of drugs, especially immunobiological drugs and drugs for the treatment of infectious diseases, through the development of its own production and scientific competencies.
Assets
As of August 2016, the holding includes:
- NPO Microgen,
- "FORT",
- MPO Metalist.
- 37% in the Kirov Plasma JV (since March 2017).
Development directions
The development of the company is carried out in five main segments of the pharmaceutical market:
- National Immunization Schedule (NCV) vaccines;
- anti-tuberculosis drugs;
- blood products;
- drugs for the treatment of HIV and hepatitis;
- insulins and its analogues.
The development strategy of the holding in 2016, in particular, provides for the production by 2020 of up to 100% of the national demand for vaccines under the NCIP and blood plasma factors in kind, up to 80% of anti-tuberculosis drugs and 20% of drugs against HIV and hepatitis B and C at the holding's facilities.
It was announced that in the future Nacimbio would unite manufacturing enterprises, research and development centers. In cooperation with Russian and foreign companies, the holding will produce the most important drugs, develop innovative drugs, build and equip new and modernized enterprises with equipment.
The plans include the creation of a number of joint ventures with partners in order to ensure the transfer of technologies and the organization of the production of medicines in a full cycle, including pharmaceutical substances, on the territory of the Russian Federation.
The total volume of investments in the development of production within the framework of the strategy until 2020 should amount to 25 billion rubles. The planned total annual revenue of the holding in 2020 is about 40 billion rubles.
Performance indicators
2015: Growth of net profit in 20 times, revenue twice
The net profit of the division of Rostec - the National Immunobiological Company (Natsimbio) - increased in 2015 by almost 20 times, to 648.5 million rubles, and revenue doubled, the Vedomosti newspaper writes, citing its report on RAS .
More than half of the revenue - about 484 million rubles. - brought financial bonuses from suppliers. The reason for the increase in profits was the same premiums, as well as fines paid by suppliers and income from the placement of free funds.
"It is up to the supplier to pay or not to pay the premium," Nacimbio's spokeswoman said. According to her, the payment is possible upon the purchase of a large consignment of goods, early payment, etc. The Nacimbio report reflects premiums under contracts executed not only in 2015, but also in 2014. It follows from the report that such premiums do not change the cost of the goods and the price of the contract and are not subject to VAT.
Premiums were paid by four suppliers - Rosta (11 million rubles), Pharmstore Company (375.3 million rubles), MBA-group (93.5 million rubles) and Pharmasyntez (4 million rubles). ).
It is assumed that in this way drug suppliers give Nacimbio a discount.
“Since they do not want to sell drugs at a price lower than the limit set by the state, they arrange supplies for Nacimbio at the limit price, and then return part of the cost in the form of premiums,” a source from the pharmacological field believes.
An employee of another pharmaceutical manufacturer supplying drugs for public procurement does not rule out that Nacimbio's suppliers are forced to lower prices in markets where this company is a monopoly.
Earlier it was reported that the pharmaceutical subsidiary of Rostec wants to absorb the insulin market.
Story
2018
The National Immunobiological Company, in connection with the development of cooperation and the merger of the pharmaceutical assets of the state corporation Rostec and the Marathon Group, as well as the change in the shareholding structure of Nacimbio itself, in February 2018 updated the composition of the Board of Directors.
Thus, for the first time three representatives of the Marathon Group joined the Nacimbio Council:
- Marathon Group President Alexander Vinokurov,
- Chairman of the Board Marathon Group Sergey Zakharov,
- director of economics and finance Marathon Group Elena Milinova.
In turn, the following members of the previous composition retained their seats in the Council:
- Deputy General Director of Rostec State Corporation Alexander Nazarov, who was also elected Chairman of the Board of Directors,
- Deputy Minister of Health of the Russian Federation Tatyana Yakovleva,
- general director of Nacimbio Andrey Zagorsky,
- Head of Financial Planning and Social Programs of the Department of Economics and Finance of Rostec State Corporation Yulia Tsvetkova.
Vitaly Mashchitsky, President of the Vi Holding Group of Companies, Advisor to the General Director of Rostec, Vitaly Mashchitsky, Executive Director of Rostec Oleg Yevtushenko, and Zhanna Skorina, Head of the Department for Judicial and Legal Work of the Legal Support and Corporate Governance Function of the State Corporation, left the Council.
Rostec received 79% of Nacimbio, while the latter will be a monopoly drug supplier
2016
Maryam Khubieva replaced Nikolai Semenov as CEO
On August 11, 2016, it was announced that Maryam Khubieva, who previously worked at Roszdravnadzor and large pharmaceutical companies, became the new CEO of Natsimbio.
Name of organization AKTSIONERNOE OBSHESTVO "NATSIONAL'NAYA IMMUNOBIOLOGICHESKAYA KOMPANIYA" TIN 7703801737 Code of type of economic activity according to OKVED classifier 74.15 Code according to OKPO 22698366 Form of ownership (OKFS) 61 - Ownership of state corporations Form of incorporation (OKOPF) 12267 - Non-public 2 joint-stock companies Report type - Full Unit of measurement 384 - Thousand rubles
Reporting for other yearsZero lines are hidden for ease of reporting.
Balance sheet
| Name of indicator | Line code | As of December 31, 2015 | As at 31 December 2014 |
| Assets | |||
| I. Non-current assets | |||
| Intangible assets | 1110 | 2 607 | 0 |
| fixed assets | 1150 | 6 413 | 68 |
| Financial investments | 1170 | 2 891 381 | 250 |
| Deferred tax assets | 1180 | 2 362 | 5 246 |
| Total for Section I | 1100 | 2 902 763 | 5 564 |
| II. current assets | |||
| Stocks | 1210 | 193 135 | 0 |
| Value added tax on acquired valuables | 1220 | 27 629 | 17 507 |
| Accounts receivable | 1230 | 45 884 | 5 924 |
| Financial investments (excluding cash equivalents) | 1240 | 35 334 | 0 |
| Cash and cash equivalents | 1250 | 1 216 711 | 1 329 515 |
| Other current assets | 1260 | 1 552 | 88 |
| Total for Section II | 1200 | 1 520 245 | 1 353 034 |
| BALANCE | 1600 | 4 423 008 | 1 358 598 |
| Passive | |||
| III. Capital and reserves | |||
| Authorized capital (share capital, authorized fund, contributions of comrades) | 1310 | 20 000 | 20 000 |
| Reserve capital | 1360 | 1 684 | 0 |
| 1370 | 635 745 | 33 686 | |
| Total for Section III | 1300 | 3 579 568 | 53 686 |
| IV. LONG TERM DUTIES | |||
| Deferred tax liabilities | 1420 | 196 | 0 |
| Total for section IV | 1400 | 196 | 0 |
| V. SHORT-TERM LIABILITIES | |||
| Accounts payable | 1520 | 832 965 | 1 278 683 |
| Estimated liabilities | 1540 | 10 279 | 26 229 |
| Section V total | 1500 | 843 244 | 1 304 912 |
| BALANCE | 1700 | 4 423 008 | 1 358 598 |
Income statement
| Name of indicator | Line code | For 2015 | For 2014 |
| Revenue Revenue is shown net of value added tax and excises. |
2110 | 6 453 786 | 3 093 474 |
| Cost of sales | 2120 | (6 036 208) | (2 976 869) |
| Gross profit (loss) | 2100 | 417 578 | 116 605 |
| Selling expenses | 2210 | (69 562) | (27 228) |
| Management expenses | 2220 | (324 967) | (49 340) |
| Profit (loss) from sales | 2200 | 23 049 | 40 037 |
| Income from participation in other organizations | 2310 | 1 188 | 0 |
| Interest receivable | 2320 | 36 573 | 0 |
| Percentage to be paid | 2330 | (2 037) | (1 332) |
| Other income | 2340 | 791 836 | 7 017 |
| other expenses | 2350 | (38 342) | (3 605) |
| Profit (loss) before tax | 2300 | 812 267 | 42 117 |
| Current income tax | 2410 | (160 671) | (13 647) |
| including permanent tax liabilities (assets) | 2421 | 1 297 | 8 |
| Change in deferred tax liabilities | 2430 | 196 | 30 |
| Change in deferred tax assets | 2450 | -2 884 | 5 246 |
| Net income (loss) | 2400 | 648 516 | 33 686 |
| Cumulative financial result of the period | 2500 | 0 | 0 |
Statement of changes in equity
| 1. Movement of capital | |||||
| Authorized capital | Own shares repurchased from shareholders | Extra capital | Reserve capital | Retained earnings (uncovered loss) | Total |
| Equity as at 31 December 2014 (3200) | |||||
| 20 000 | (0) | 0 | 0 | 33 686 | 53 686 |
| (2015) | |||||
| Capital increase - total: (3310) | |||||
| 0 | 0 | 0 | 0 | 648 516 | 3 570 655 |
| including: net profit (3311) |
648 516 | 648 516 | |||
| property revaluation (3312) | 0 | 0 | 0 | ||
| income attributable directly to capital increases (3313) | 0 | 0 | 0 | ||
| additional issue of shares (3314) | |||||
| 0 | 0 | 0 | 0 | ||
| increase in the par value of shares (3315) | |||||
| 0 | 0 | 0 | 0 | ||
| reorganization of a legal entity (3316) | |||||
| 0 | 0 | 0 | 0 | 0 | 0 |
| Decrease in capital - total: (3320) | |||||
| (0) | 0 | (0) | (0) | (44 772) | (44 772) |
| including: loss (3321) |
(0) | (0) | |||
| property revaluation (3322) | (0) | (0) | (0) | ||
| expenses relating directly to depreciation of equity (3323) | (0) | (0) | (0) | ||
| decrease in the par value of shares (3324) | |||||
| (0) | 0 | 0 | 0 | (0) | |
| decrease in the number of shares (3325) | |||||
| (0) | 0 | 0 | 0 | (0) | |
| reorganization of a legal entity (3326) | |||||
| 0 | 0 | 0 | 0 | 0 | (0) |
| dividends (3327) | (44 772) | (44 772) | |||
| Changes in additional capital (3330) | 0 | 0 | 0 | ||
| Changes in reserve capital (3340) | 1 684 | -1 684 | |||
| Equity as at 31 December 2015 (3300) | |||||
| 20 000 | (0) | 0 | 1 684 | 635 745 | 3 579 568 |
Cash flow statement
| Name of indicator | Line code | For 2015 |
| Cash flows from current operations | ||
| Income - total including: |
4110 | 6 951 497 |
| from the sale of products, goods, works and services | 4111 | 6 336 908 |
| lease payments, license payments, royalties, commissions and other similar payments | 4112 | 0 |
| from the resale of financial investments | 4113 | 0 |
| other supply | 4119 | 0 |
| Payments - total including: |
4120 | (7 047 850) |
| to suppliers (contractors) for raw materials, materials, works, services | 4121 | (6 338 848) |
| in connection with the remuneration of employees | 4122 | (160 131) |
| interest on debt obligations | 4123 | (2 037) |
| corporate income tax | 4124 | (115 628) |
| other payments | 4129 | (84 993) |
| Balance of cash flows from current operations | 4100 | -96 353 |
| Cash flows from investment operations | ||
| Income - total including: |
4210 | 210 |
| from the sale of non-current assets (except for financial investments) | 4211 | 0 |
| from the sale of shares of other organizations (participatory interests) | 4212 | 0 |
| from the return of loans granted, from the sale of debt securities (rights to claim funds from other persons) | 4213 | 0 |
| dividends, interest on debt financial investments and similar income from equity participation in other organizations | 4214 | 210 |
| other supply | 4219 | 0 |
| Payments - total including: |
4220 | (8 245) |
| in connection with the acquisition, creation, modernization, reconstruction and preparation for the use of non-current assets | 4221 | (6 495) |
| in connection with the acquisition of shares of other organizations (participation interests) | 4222 | (1 750) |
| in connection with the acquisition of debt securities (the rights to claim funds from other persons), the provision of loans to other persons | 4223 | (0) |
| interest on debt obligations included in the cost of an investment asset | 4224 | (0) |
| other payments | 4229 | (0) |
| Balance of cash flows from investment operations | 4200 | -8 035 |
| Cash flows from financial transactions | ||
| Income - total including: |
4310 | 147 131 | obtaining credits and loans | 4311 | 147 126 |
| cash deposits of owners (participants) | 4312 | 0 |
| from issuance of shares, increase in participation | 4313 | 5 | from the issuance of bonds, bills of exchange and other debt securities, etc. | 4314 | 0 |
| other supply | 4319 | 0 |
| Payments - total including: |
4320 | (155 547) |
| owners (participants) in connection with the redemption of shares (participatory interests) of the organization from them or their withdrawal from the membership | 4321 | (0) |
| for the payment of dividends and other payments for the distribution of profits in favor of the owners (participants) | 4322 | (8 421) |
| in connection with the redemption (redemption) of promissory notes and other debt securities, repayment of credits and loans | 4323 | (147 126) |
| other payments | 4329 | (0) |
| Balance of cash flows from financial operations | 4300 | -8 416 |
| Balance of cash flows for the reporting period | 4400 | -112 804 |
| Balance of cash and cash equivalents at the beginning of the reporting period | 4450 | 0 |
| Balance of cash and cash equivalents at the end of the reporting period | 4500 | 0 |
| The magnitude of the impact of changes in the foreign exchange rate against the ruble | 4490 | 0 |
Information is generated from the set of open data "Accounting (financial) statements of enterprises and organizations for 2015" of the Federal State Statistics Service (Rosstat)
Pharmaceutical holding for the development and production of immunobiological drugs
Pharmaceutical holding engaged in the development, production and supply of immunobiological drugs.
The mission of the holding is to promote the development of enterprises in the Russian immunobiological industry and ensure national sovereignty in the production and supply of immunobiological drugs, the lack of production of which in the Russian Federation poses a threat to national health security.
CEO of the company - Andrey Yurievich Zagorsky.
Holding history
Nacimbio was established by the Rostec State Corporation in 2013 with the aim of developing the production of immunobiological drugs important for national security. To do this, the holding was given shares in two pharmaceutical enterprises - the Sintez Kurgan plant (one of the ten leaders in the domestic pharmaceutical industry in terms of production volume) and the FORT research and production complex - a modern full-cycle production facility in the Ryazan region. Later, the company was transferred the powers of the sole executive body of the largest domestic manufacturer of immunobiological drugs NPO Microgen.
Currently, the number of employees of all enterprises of the holding is more than 8 thousand people.
Nacimbio today
The company is one of the largest players in the Russian pharmaceutical market, with a total output of over 250 million drug packs per year at three production sites. The development of the company is carried out in five main segments: vaccines and toxoids of the current and future National Immunization Schedule; blood products; bacteriophages; allergens and allergoids.
The Holding and its enterprises contribute to ensuring national immunobiological security by supplying almost 90% of the vaccines of the National Immunization Schedule (in kind), bacteriophages for emergency prevention in emergency areas, as well as vaccines used according to epidemic indications - including against tick-borne encephalitis, rabies, etc. Acting as the sole supplier, Nacimbio also contributes to expanding the coverage of influenza vaccination by increasing the annual volume of production and supply of preventive drugs. So, for a nationwide campaign during the influenza and SARS season in 2017-2018. Nacimbio donated more than 62.3 million doses of vaccines produced entirely from Russian raw materials for the needs of the state, which is 4 million doses more than a year earlier.
One of Nacimbio's strategic goals is to localize the production of new vaccines in Russia. As part of the development of technology transfer projects, in cooperation with foreign companies, Nacimbio plans to produce innovative vaccines, the production of which is not available in the Russian Federation. In particular, agreements between FORT and the American company MSD on the localization of vaccines against rotavirus infection, chicken pox and HPV, as well as between PharmAid Ltd (JV with Ishvan Pharmaceutical Ltd) and the Indian Serum Institute of India on technology transfer have been signed and are in force. rotavirus vaccine production.
Products of Nacimbio enterprises
The product portfolio of the holding's enterprises includes more than 300 international non-proprietary names (INN) of medicines.
NPO Microgen is a developer of unique domestic medicines. Among them are vaccines for the prevention of highly contagious infectious diseases such as measles, rubella, influenza and a number of others. The company is a manufacturer of the only domestic botulinum toxin type A - the drug is produced under the Relatox brand, a line of blood products - immunoglobulins, albumin, combined preparations of bacteriophages and many others.
Kurgan "Synthesis" occupies a leading position in the market of antibiotics among domestic manufacturers, and the enterprise "FORT" produces a split vaccine for the prevention of influenza that meets all WHO recommendations - "Ultrix®". In 2019, FORT launched the innovative quadrivalent influenza vaccine Ultrix® Quadri on the market.
Development and innovation
Nacimbio enterprises have an extensive portfolio of candidate drugs at various stages of development. In particular, clinical trials are being conducted to expand the indications for the use of Relatox in the field of neurology. New bacteriophages have been developed and are being studied, much attention is paid to vaccines: the third phase of clinical trials of a vaccine against rotavirus infection has been completed, and the combined vaccine for the prevention of measles, rubella and mumps "Vaktrivir" is awaiting registration. In 2019, Russia's first five-component combined vaccine for the prevention of diphtheria, tetanus, whooping cough, hepatitis B and Haemophilus influenzae was approved for use.
The company includes:
JSC NPO Microgen
LTD. "FORT"
JSC Sintez
Let's pay attention to one of the enterprises in the "orbit" "Natsimbio" - LLC "Fort". It was created in 2011. The plant in the Ryazan region was built using borrowed funds from VEB secured by the company's shares. By the beginning of 2017, 25.01% of the company was owned by Nacimbio, the remaining 74.99% was controlled (directly and through Megard Group, owned by his son) Anton Katlinsky, former Deputy Minister of Health, former CEO of NPO Microgen and former Deputy CEO RT-Biotechnologies (subsidiary of Rostec). In other words, "Fort" was actually created by a native of "Rostec" under the receipt of state contracts for the supply of medicines and was controlled by him.
In 2016, three state contracts were concluded between the Ministry of Health and Nacimbio for the supply of influenza vaccine for a total of 4.15 billion rubles. Four types of vaccine were supplied:
- Sovigripp. Producer - Federal State Unitary Enterprise "NPO "MICROGEN"". Since 2015, Microgen has been subordinate to the Ministry of Health, now it is a 100% subsidiary of Rostec.
- Ultrix. Producer - LLC "Fort" (Ryazan region). Owned by Nacimbio by 25%.
- Grippol. Producer - Federal State Unitary Enterprise SPbNIIVS FMBA of Russia, 100% state-owned enterprise.
- Grippol plus. The manufacturer is NPO Petrovax Pharm LLC (Moscow and the Moscow Region), the controlling stake belongs to Vladimir Potanin's Interros holding.
"Grippol" was supplied at 68,000 rubles. per thousand doses, Grippol Plus and Ultrix - 119,075 rubles each. for a thousand doses. Everything is more complicated with Sovigripp: under one contract, with Microgen, it cost the Ministry of Health 68,000 rubles. for a thousand doses, and in another way, with "Fort", - at 119,075 rubles. for a thousand doses. Those. the same drug for one year was purchased from one manufacturer for 75% more than from another. Recall that the Ministry of Health actually paid, and contracts with manufacturers were concluded by Nacimbio. It was this company that determined which of the manufacturers would receive how much budgetary money.
Now let's take a closer look at these deliveries. According to the published purchases of these vaccines from manufacturers, Nacimbio purchased 5,571,471 thousand doses of the Grippol Plus vaccine from NPO Petrovax Pharm and 9,150,000 doses of the Ultrix vaccine from Fort. These data can be compared with information from the public procurement website, including acceptance certificates for vaccines actually delivered to medical institutions. According to this information, hospitals received 5,568,221 doses of Grippol Plus, 2,525,769 doses of Ultrix, and 6,624,231 doses of Sovigripp, which was not purchased from manufacturers.
There is reason to believe that Fort supplied the institutions of the Ministry of Health with a cheaper Sovigripp (the cost from the manufacturer is 67,891.2 rubles), and Nacimbio paid for this vaccine as Ultrix - at a price of 119,000 rubles. The amount of the overpayment received by Fort is 338,556,497.33 rubles.
The situation repeats itself in 2017. On the same day, May 16, 2017, the Ministry of Health concludes two state contracts with Nacimbio for the supply of Sovigripp. And again, the vaccine is purchased from Microgen for 68,000 rubles. per thousand doses (a total of 39,744,329 doses were purchased), and from Fort - 119,075 rubles each. per thousand doses (in total, 5,994,945 thousand doses were purchased). Overpayment in favor of "Fort" - 306,191,815.88 rubles.
The total amount of overpayment to Fort for two years amounted to
RUB 644,748,313.21
It should be noted separately that the license agreement between Microgen and Fort for the production of the Sovigripp vaccine was concluded on June 7, 2017. Up to this point, Fort could only act as an intermediary between Microgen and the Ministry of Health.
All purchases of Nacimbio.xlsx
(Because procurement contracts and drug supply contracts use different units of measure (e.g., thousands of doses and packs), all prices and quantities of goods have been converted into a single form: thousands of doses for vaccines and IU (medical units) for blood products).
So, "Natsimbio" significantly overpaid "Fort" in comparison with similar deliveries of another company. And after that, in May 2017, it was announced that the share of Anton Katlinsky in Fort was being bought out by entrepreneur Alexander Vinokurov, the owner of the pharmaceutical company Marathon Group. And in August 2017, the general director of Nacimbio, Mariam Khubieva, left her position and went to work for Vinokurov at Marathon. And Katlinsky became an adviser to the general director of Nacimbio.
Loading...